CRBP
NASDAQ
US
Corbus Pharmaceuticals Holdings, Inc. - Common Stock
$10,17
▲ +$0,19
(+1,90%)
Vol. 236K
2
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$142.9M
ROE
-57,1%
Margine
-2838,7%
D/E
0,00
Beta
2,86
52W
$5–$21
Consenso Wall Street
16 analisti · Apr 20266
Acquisto forte
9
Compra
1
Mantieni
0
Vendi
0
Vendita forte
93,8%
Rating Compra
Grafico dei Prezzi
Titoli simili
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
MGNX
MacroGenics Inc
$101.8M
CRBU
Caribou Biosciences Inc
$148.6M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
GALT
Galectin Therapeutics Inc
$268.2M
ACHV
Achieve Life Sciences Inc
$264.6M
SGMT
Sagimet Biosciences Inc
$183.5M
CNTN
Canton Strategic Holdings Inc
Utili
Tasso di battuta: 50,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-1,61 | $-1,25 | +$0,36 |
| Set 2025 | $-1,74 | $-1,90 | $-0,16 |
| Giu 2025 | $-1,54 | $-1,44 | +$0,10 |
| Mar 2025 | $-1,31 | $-1,39 | $-0,08 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$13.8M | -$9.5M | -$17.0M | -$17.7M | -$23.3M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -43.6% | -43.6% | -43.6% | -43.6% | -43.6% | -57.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -2838.7% | -2838.7% | -2838.7% | -2838.7% | -2838.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 6.31 |
Rapporti chiave
ROA (TTM)
-50,9%
P/S (TTM)
92,18
P/B
1,0
EPS (TTM)
$-5,51
CF/Share
$-10,98
52W High
$20,56
52W Low
$4,64
$4,64
Intervallo 52 settimane
$20,56
Salute finanziaria
Flusso di cassa libero
-$15.6M
Debito netto
-$24.9M
Liquidità
$27.0M
Debito totale
$2.0M
Aggiornato al Set 30, 2025
Як CRBP виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CRBP vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
92,2
▲
617%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
1,0
▼
59%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CRBP vs аналоги Biotechnology
ROE
-57,1%
▲
15%
sopra
peer
(-67,3%)
vs Peer
vs Settore
In linea
Net margin
-2838,7%
▼
890%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-50,9%
▼
9%
sotto
peer
(-46,7%)
vs Peer
vs Settore
In linea
Фінансове здоровʼя CRBP vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
6,3
▲
42%
sopra
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
2,9
▲
195%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CRBP
CRBP
Mediana peer
Industria
CRBP прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CRBP vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
SMETHURST DOMINIC
Officer · Mar 02
6097 shs
HODGSON IAN
Chief Operating Officer · Feb 17
847 shs
MORAN SEAN F
Chief Financial Officer · Feb 13
4701 shs
COHEN YUVAL
Chief Executive Officer · Feb 13
13871 shs
SMETHURST DOMINIC
Officer · Feb 03
3285 shs
HODGSON IAN
Chief Operating Officer · Feb 03
2415 shs
MORAN SEAN F
Chief Financial Officer · Gen 14
28082 shs
COHEN YUVAL
Chief Executive Officer · Gen 14
50000 shs
SMETHURST DOMINIC
Officer · Gen 14
28365 shs
HODGSON IAN
Chief Operating Officer · Gen 14
28365 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 39,91%Cormorant Asset Management,…
13,22%
$20.4M
Orbimed Advisors LLC.
9,01%
$13.9M
Aberdeen Group plc
7,45%
$11.5M
Octagon Capital Advisors LP
5,38%
$8.3M
Vanguard Group Inc
4,85%
$7.5M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora